Patent · US Expired

N-terminally truncated galectin-3 for use in treating cancer

US6770622B2 · kind B2 · utility

17Cited by

36References

2Claims

0Family size

Inventors

Gary Jarvis · San Francisco, US
Constance John · San Francisco, US
Hakon Leffler · Lund, SE

Key dates

Filing date	Jun 8, 2001
Grant date	Aug 3, 2004
Priority date	—
Expiry date	Jun 8, 2021

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/1709
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided a composition having an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.